Liminatus Pharma, Inc. Warrants (LIMNW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LIMNW SEC filings page.
This page shows Liminatus Pharma, Inc. Warrants (LIMNW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Balance-sheet contraction is the dominant mechanic, with negative equity leaving obligations poorly supported by reported assets.
Total assets fell from$5.4M in FY2024 to$513K in FY2025, shrinking the asset base available to support the business. By FY2025, liabilities were 20.1x assets, so the balance sheet’s solvency profile depended more on obligations than on asset backing.
Short-term liquidity tightened sharply: the current ratio declined from 0.2x in FY2024 to 0.0x in FY2025, meaning reported current assets represented only a small fraction of current obligations.
In FY2024, operating cash flow was
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Liminatus Pharma, Inc. Warrants does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Liminatus Pharma, Inc. Warrants's EBITDA was -$1.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is down 25.3%.
Liminatus Pharma, Inc. Warrants reported -$1.4M in net income in Q2 2026. This represents a decrease of 1342.2% from the same quarter a year earlier. Against the prior quarter it is down 25.2%.
Liminatus Pharma, Inc. Warrants earned -$0.03 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Cash & Balance Sheet
Liminatus Pharma, Inc. Warrants held $3.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Liminatus Pharma, Inc. Warrants's ROE was -468.1% in Q2 2026, measuring profit generated per dollar of shareholder equity.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Liminatus Pharma, Inc. Warrants invested $600K in research and development in Q2 2026. Against the prior quarter it is up 50.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
LIMNW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $600K | $400K | N/A | N/A | N/A | N/A | N/A | $357K |
| SG&A Expenses | $779K-30.3% | $701K+165.3% | N/A | $701K+276.8% | $1.1M+473.2% | $264K | N/A | $186K |
| Operating Income | -$1.4M-23.3% | -$1.1M-316.7% | N/A | -$701K-29.1% | -$1.1M-23.0% | -$264K-106871.7% | N/A | -$543K |
| EBITDA | -$1.4M | -$1.1M | N/A | -$701K | N/A | N/A | N/A | N/A |
| Interest Expense | $19K-69.7% | $19K-83.9% | N/A | $19K-79.4% | $62K-19.3% | $116K | N/A | $93K |
| Net Income | -$1.4M-1342.2% | -$1.1M-243.1% | N/A | -$1.8M-203.2% | $113K+111.8% | -$328K+81.3% | N/A | -$601K |
| EPS (Basic) | -$0.03 | -$0.03-50.0% | -$0.34-3300.0% | -$0.07-133.3% | $0.00+100.0% | -$0.02+99.2% | -$0.01 | -$0.03 |
| EPS (Diluted) | -$0.03 | -$0.03 | -$0.34 | -$0.07-133.3% | $0.00+100.0% | -$0.02 | -$0.01 | -$0.03 |
| Diluted Shares (Avg) | 48M | 36M | N/A | 27M+54.3% | 23M+33.1% | 18M | N/A | 18M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
LIMNW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.4M+78.3% | $2.8M+114.2% | $513K-90.5% | $1.3M | $1.9M | -$19.7M | $5.4M | N/A |
| Current Assets | $3.4M+90.3% | $2.8M | $501K-90.5% | $1.2M | $1.8M | N/A | $5.3M | N/A |
| Cash & Equivalents | $3.0M+125.5% | $1.9M | $338K | $725K | $1.3M | $0 | $0 | N/A |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Total Liabilities | $3.1M-71.0% | $2.9M+275640.1% | $10.3M-58.3% | $3.0M | $10.7M | $1K | $24.7M | N/A |
| Current Liabilities | $3.0M-71.1% | $2.9M | $10.3M-58.4% | $2.9M | $10.5M | N/A | $24.7M | N/A |
| Non-Current Liabilities | $63K-68.7% | $33K | $29K | $124K | $200K | N/A | $0 | N/A |
| Total Equity | $301K+103.4% | -$133K+99.3% | -$9.8M+49.3% | -$1.6M+91.4% | -$8.8M+52.4% | -$19.7M-12.1% | -$19.3M | -$19.1M |
| Retained Earnings | -$41.4M-43.4% | -$40.0M-3773055.4% | -$38.9M-35.6% | -$30.7M | -$28.9M | -$1K | -$28.7M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LIMNW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$970K+89.0% | -$2.0M-1164.4% | -$387K-175.0% | -$601K-191.4% | -$8.8M-698.4% | -$159K | -$141K | -$206K |
| Depreciation & Amortization | $468 | $518 | $543 | $542 | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$387K | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | $0+100.0% | -$13K+98.4% | -$200K | -$575K | -$550K | -$800K |
| Financing Cash Flow | $2.1M | $3.6M+402.8% | $0-100.0% | $0-100.0% | N/A | $713K | $700K | $1.0M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
LIMNW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$9.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.05), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Liminatus Pharma, Inc. Warrants Ranks
Frequently Asked Questions
What are Liminatus Pharma, Inc. Warrants's total assets?
Liminatus Pharma, Inc. Warrants (LIMNW) had $513K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Liminatus Pharma, Inc. Warrants's capital expenditures?
Liminatus Pharma, Inc. Warrants (LIMNW) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Liminatus Pharma, Inc. Warrants's current ratio?
Liminatus Pharma, Inc. Warrants (LIMNW) had a current ratio of 0.05 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is Liminatus Pharma, Inc. Warrants's debt-to-equity ratio negative or not reported?
Liminatus Pharma, Inc. Warrants (LIMNW) has negative shareholder equity of -$9.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.